-
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely
Monday, April 21, 2025 - 1:58pm | 501Read More...Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 12 months. But with a 3.5% pullback in the past month, all eyes are now on its first-...
-
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Monday, April 7, 2025 - 12:11pm | 414Read More...Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx. Journavx Gains Early Traction At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after...
-
JPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street Sentiment
Monday, March 11, 2019 - 2:33pm | 318Read More...Mersana Therapeutics Inc (NASDAQ: MRSN) shares, which went public in March 2018, was hit with its first bearish rating Monday in the absence of any stock-impacting data readouts over the next 12 months. The Analyst JPMorgan analyst Jessica Fye downgraded Mersana from Neutral to Underweight and...
-
Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In Portfolio Rebalancing
Monday, March 19, 2018 - 12:45pm | 502Read More...JPMorgan is generally bullish on biotech and in most cases sees opportunity for longer-term upside, but its ratings strategy dictates the sidelining of lower conviction stocks. Here's a look at biotech companies JPMorgan turned bearish on Monday. The Rating Analyst Jessica Fye...
-
Cempra Is 'A Good Drug For Bad Bugs,' Says JPMorgan
Tuesday, July 12, 2016 - 10:02am | 329Read More...JPMorgan’s Jessica Fye believes a key driver for Cempra Inc (NASDAQ: CEMP) will be Solithera, a new antibiotic for community acquired pneumonia (CABP) in adults. Fye initiated coverage of the company with an Overweight rating and price target of $31. Potential For Solithera “With the...
-
BioCryst Downgraded By JPMorgan, Analysts Await 'More Data'
Tuesday, February 9, 2016 - 9:51am | 300Read More...The share price of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has plunged 82.53 percent over the past one year, reaching within two cents of its 52-week low on February 8. JPMorgan’s Jessica Fye has downgraded the rating on the company from Overweight to Neutral, while lowering the...
-
JPMorgan Reiterates Overweight On Medicines Co, Sees $50 Per Share On DCF Basis
Friday, January 22, 2016 - 10:53am | 311Read More...The share price of The Medicines Company (NASDAQ: MDCO) has appreciated 41.79 percent over the past year, from $27.50 on January 22, 2015. JPMorgan’s Jessica Fye has reiterated an Overweight rating on the company, with a price target of $50. Following the recent sale of the company...
-
JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition'
Tuesday, August 19, 2014 - 2:02pm | 180Read More...Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) are up almost 20 percent over the past five trading sessions. JP Morgan started coverage of the company with an Overweight rating and $190 price target. "In the context of an ongoing wave of consolidation in the specialty pharmaceuticals...
-
Warner Chilcott is JP Morgan's Top Pick Within Specialty Pharmaceuticals (WCRX)
Thursday, June 10, 2010 - 11:02am | 151Read More...Warner Chilcott (NASDAQ: WCRX) will likely be added to the Russell 1000 on Friday, June 11 and should serve as an NT catalyst for the shares. An inclusion in the S&P 500 later this year is also possible. JP Morgan analysts Chris Schott, Dewey Steadman, and Jessica Fye rate WCRX Overweight. The...
-
Forest Laboratories (FRX) Shares Climb 5.6%
Tuesday, May 18, 2010 - 6:09pm | 115Read More...Shares of Forest Laboratories Inc. (NYSE: FRX) closed Tuesday trading up 5.65% at $27.67 per share. Forest Laboratories Inc. opened Tuesday morning at $27.87 per share, and didn't show many dramatic movements for the rest of the day, trading between $27.22 and $28.14 per share. Volume of nearly 15...
-
J.P. Morgan Rates Forest Laboratories (FRX) Underweight
Tuesday, May 18, 2010 - 9:50am | 190Read More...J.P. Morgan analysts Chris Schott, Dewey Steadman and Jessica Fye maintained their rating of Underweight for shares of Forest Laboratories, Inc. (NYSE: FRX), with a price target of $27 per share. The analysts said that it's unlikely that Daxas will prove to be a meaningful earnings driver for...
